

Policy on Indirect Cost

The mission of Ellison Medical Institute (EMI) is to spark innovation, leverage technology, and drive interdisciplinary, patient-centered research to continually enhance health, reimagine and redefine cancer care, and transform lives.

To optimize the use of its financial resources towards public good and ensure funds are dedicated to activities that have the most significant impact on healthcare outcomes, EMI limits indirect costs (IDC) to 15% of total direct costs of a project, unless otherwise agreed upon or informed by market trends.

The decision to limit IDC to 15% is rooted in principles of fiscal responsibility and mission alignment. Capping IDC ensures that a larger portion of EMI's budget is directed towards high-impact areas, such as direct costs to support prevention and treatment of cancer and other complex diseases, innovative research, development, and other critical activities.

This policy has been approved April 2025.